E-688 / Palleon Pharma, Fosun Pharma - LARVOL DELTA

Human sialidase-armed anti-B7-H3 antibody that enhances innate and adaptive antitumor immune responses (AACR 2026) - P1/2 | "Here we report that fusion of the engineered human sialidase to anti-B7-H3 nanobody, designated E-688 (also called HLX316) significantly improves tumor desialylation depth, durability, and efficacy in vitro and in vivo, while maintaining a favorable safety profile. Its clinical development is supported by strong in vitro, in vivo, and GLP toxicology data. Additional targets are currently in development to support a platform-based approach."

IO biomarker • Oncology • CD276